mitotane has been researched along with Pituitary ACTH Hypersecretion in 14 studies
Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.
Pituitary ACTH Hypersecretion: A disease of the PITUITARY GLAND characterized by the excess amount of ADRENOCORTICOTROPIC HORMONE secreted. This leads to hypersecretion of cortisol (HYDROCORTISONE) by the ADRENAL GLANDS resulting in CUSHING SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome." | 7.81 | Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. ( Bachelot, A; Baudin, E; Bernard, V; Bry-Gauillard, H; Chanson, P; Crinière, L; Do Cao, C; Droumaguet, C; Guignat, L; Leboulleux, S; Maiter, D; Pierre, P; Salenave, S; Santulli, P; Schlumberger, M; Touraine, P; Young, J, 2015) |
| "Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome." | 3.81 | Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. ( Bachelot, A; Baudin, E; Bernard, V; Bry-Gauillard, H; Chanson, P; Crinière, L; Do Cao, C; Droumaguet, C; Guignat, L; Leboulleux, S; Maiter, D; Pierre, P; Salenave, S; Santulli, P; Schlumberger, M; Touraine, P; Young, J, 2015) |
| "Medical therapy to control hypercortisolism in adrenal Cushing's syndrome is currently not the first-line therapy." | 2.66 | What is the role of medical therapy in adrenal-dependent Cushing's syndrome? ( Braun, LT; Reincke, M, 2020) |
| "Medical therapy for Cushing disease is primarily used to control hypercortisolism in patients whose disease persists or with recurrent disease after pituitary surgery, including those awaiting the salutary effects of radiation therapy." | 2.61 | Medical Management of Cushing Disease. ( Biller, BMK; Tritos, NA, 2019) |
| "OBJECT Cushing's disease (CD) can lead to significant morbidity secondary to hormonal sequelae or mass effect from the pituitary tumor." | 2.52 | Cushing's disease: current medical therapies and molecular insights guiding future therapies. ( Aghi, MK; Lau, D; Rutledge, C, 2015) |
| "Pasireotide was the only treatment to be assessed in a randomized trial and was supported by a 'moderate' level of evidence." | 2.50 | Efficacy of medical treatment in Cushing's disease: a systematic review. ( Gadelha, MR; Vieira Neto, L, 2014) |
| "Hypercortisolism induced by Cushing disease causes high morbidity and mortality." | 2.48 | New prospects for drug treatment in Cushing disease. ( Barahona Constanzo, MJ; del Pozo Picó, C, 2012) |
| "The goals of ideal medical therapy for Cushing's disease should be to target the aetiology of the disorder, and thus surgery is the current 'gold standard' treatment." | 2.46 | Medical therapy of Cushing's disease: where are we now? ( Alexandraki, KI; Grossman, AB, 2010) |
| "Medical therapy for Cushing's disease (CD) is currently based on agents mainly targeting adrenocortical function." | 1.39 | Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. ( Ambrosio, MR; Degli Uberti, EC; Gentilin, E; Lapparelli, M; Minoia, M; Tagliati, F; Terzolo, M; Zatelli, MC; Zoli, M, 2013) |
| "Mitotane is a potent anti-cortisolic drug but has been rarely investigated in the treatment of CD." | 1.38 | Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center. ( Abbas, H; Baudry, C; Bertagna, X; Bertherat, J; Bou Khalil, R; Coste, J; Guibourdenche, J; Guignat, L; Legmann, P; Silvera, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Golinelli, S | 1 |
| Fracassi, F | 1 |
| Bianchi, E | 1 |
| Pöppl, ÁG | 1 |
| Miceli, DD | 1 |
| Benedicenti, L | 1 |
| De Marco, V | 1 |
| Cook, AK | 1 |
| Espada Castro, L | 1 |
| Ramsey, I | 1 |
| Seo, KW | 1 |
| Cantile, C | 1 |
| Gandini, G | 1 |
| Hulsebosch, SE | 1 |
| Feldman, EC | 1 |
| Tritos, NA | 2 |
| Biller, BMK | 2 |
| Braun, LT | 1 |
| Reincke, M | 1 |
| Gentilin, E | 1 |
| Tagliati, F | 1 |
| Terzolo, M | 1 |
| Zoli, M | 1 |
| Lapparelli, M | 1 |
| Minoia, M | 1 |
| Ambrosio, MR | 1 |
| Degli Uberti, EC | 1 |
| Zatelli, MC | 1 |
| Gadelha, MR | 1 |
| Vieira Neto, L | 1 |
| Broder, MS | 1 |
| Neary, MP | 1 |
| Chang, E | 1 |
| Cherepanov, D | 1 |
| Sun, GH | 1 |
| Ludlam, WH | 1 |
| Salenave, S | 1 |
| Bernard, V | 1 |
| Do Cao, C | 1 |
| Guignat, L | 2 |
| Bachelot, A | 1 |
| Leboulleux, S | 1 |
| Droumaguet, C | 1 |
| Bry-Gauillard, H | 1 |
| Pierre, P | 1 |
| Crinière, L | 1 |
| Santulli, P | 1 |
| Touraine, P | 1 |
| Chanson, P | 1 |
| Schlumberger, M | 1 |
| Maiter, D | 1 |
| Baudin, E | 1 |
| Young, J | 1 |
| Lau, D | 1 |
| Rutledge, C | 1 |
| Aghi, MK | 1 |
| Murao, K | 1 |
| Imachi, H | 1 |
| Ishida, T | 1 |
| Hosomi, N | 1 |
| Masugata, H | 1 |
| Alexandraki, KI | 1 |
| Grossman, AB | 1 |
| Baudry, C | 1 |
| Coste, J | 1 |
| Bou Khalil, R | 1 |
| Silvera, S | 1 |
| Guibourdenche, J | 1 |
| Abbas, H | 1 |
| Legmann, P | 1 |
| Bertagna, X | 1 |
| Bertherat, J | 1 |
| Barahona Constanzo, MJ | 1 |
| del Pozo Picó, C | 1 |
| Feelders, RA | 1 |
| Hofland, LJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism[NCT01990560] | Phase 4 | 8 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in hyperglycemia assessed by HbA1c, also known as glycated hemoglobin (NCT01990560)
Timeframe: Baseline, 3 months, and 6 months
| Intervention | percentage of red blood cells (Mean) | ||
|---|---|---|---|
| Baseline | 3 months | 6 months | |
| Mifepristone | 6.2 | 6.1375 | 6.125 |
Change in metabolic syndrome as assessed by BMI (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | kg/m2 (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 35.1538 | 34.5463 |
Change in Quality of Life - as assessed by the Cushing's Quality of Life questionnaire (CushingQoL). Patient completed questionnaire, 12 items, each scored on a 5 point score, resulting in a score of 12 (worst) to 60 (best) where higher scores indicate more favorable QOL. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 37.2857 | 38.7857 |
Change in metabolic syndrome as assessed by fasting lipid profile which includes Low-density lipoproteins ( LDL), High-density lipoproteins (HDL), and Triglycerides (Trigs) levels, and total cholesterol which is the sum of HDL plus LDL and 20% of trigs. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total Cholesterol Baseline | Total Cholesterol 6 months | LDL baseline | LDL 6 months | HDL Baseline | HDL 6 months | Trigs Baseline | Trigs 6 months | |
| Mifepristone | 178.63 | 171.43 | 97.88 | 104.37 | 59.13 | 46.86 | 107.88 | 100.29 |
Change in hyperglycemia assessed by Homeostatic Model Assessment of Insulin Resistance, HOMA-IR (a validated assessment of insulin resistance). HOMA-IR = fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | HOMA-IR score (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 2.418 | 1.465 |
Change in Quality of Life as assessed by the Hospital Anxiety and Depression Scale (HADS). Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 16.2857 | 11.1667 |
Change in Quality of Life as assessed by the Nottingham Health Profile (NHP) which is a patient reported questionnaire to measure a patient's view of their own health status. There are 6 sections (Energy level, Pain, Emotional Reaction, Sleep, Social Isolation, and Physical Abilities. All questions have only yes/no answer options and each section score is weighted so that the possible score range for any section is 0-100. The higher the score, the greater the number and severity of problems. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Energy Level (EL) Baseline | EL 6 months | Pain (P) Baseline | P 6 months | Emotional Reaction (ER) Baseline | ER 6 months | Sleep (S) Baseline | S 6 months | Social Isolation (SI) Baseline | SI 6 months | Physical Abilities (PA) Baseline | PA 6 months | |
| Mifepristone | 32.60 | 45.40 | 24.88 | 32.08 | 27.03 | 35.09 | 24.87 | 31.15 | 20.09 | 31.15 | 23.06 | 27.49 |
Change in Quality of Life as assessed by the Beck Depression Inventory. a 21-question multiple choice, self-report inventory that is used for measuring the severity of anxiety. Scoring is from a 0 (not at all) to 3 (severe) with a total score range of 0-63. Higher total scores indicate more severe anxiety symptoms. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 16.1429 | 11.7143 |
Change in Quality of Life - as assessed by the State Trait Anxiety Inventory (STAI). The State-Trait Anxiety Inventory both state and trait anxiety separately. Each type of anxiety has its own scale of 20 different questions that are scored and averaged. Total scores range from 20 to 80, with higher scores correlating with greater anxiety. (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 25.4286 | 28.8571 |
Change in metabolic syndrome as assessed by waist circumference (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | cm (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 103.25 | 99.3125 |
Change in metabolic syndrome as assessed by weight (NCT01990560)
Timeframe: Baseline and 6 months
| Intervention | kg (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Mifepristone | 99.57 | 97.75 |
8 reviews available for mitotane and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Medical Management of Cushing Disease.
Topics: Cabergoline; Etomidate; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH Hypersecretion; S | 2019 |
What is the role of medical therapy in adrenal-dependent Cushing's syndrome?
Topics: Adrenal Gland Diseases; Cushing Syndrome; Humans; Ketoconazole; Metyrapone; Mitotane; Pituitary ACTH | 2020 |
Advances in the Medical Treatment of Cushing Disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Cabergoline; Endocrinology; Humans; Mifepristone; Mitotan | 2020 |
Efficacy of medical treatment in Cushing's disease: a systematic review.
Topics: Cabergoline; Ergolines; Female; Humans; Ketoconazole; Male; Metyrapone; Mitotane; Pituitary ACTH Hyp | 2014 |
Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Topics: Clinical Trials as Topic; Drug Delivery Systems; Female; Forecasting; Humans; Male; Mitotane; Pituit | 2015 |
Medical therapy of Cushing's disease: where are we now?
Topics: Dopamine Agonists; Humans; Hydrocortisone; Ketoconazole; Metyrapone; Mifepristone; Mitotane; Pituita | 2010 |
New prospects for drug treatment in Cushing disease.
Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trial | 2012 |
Medical treatment of Cushing's disease.
Topics: Antineoplastic Agents, Hormonal; Dopamine Agonists; Humans; Mitotane; Octreotide; Pituitary ACTH Hyp | 2013 |
6 other studies available for mitotane and Pituitary ACTH Hypersecretion
| Article | Year |
|---|---|
Clinical features of muscle stiffness in 37 dogs with concurrent naturally occurring hypercortisolism.
Topics: Animals; Cushing Syndrome; Dog Diseases; Dogs; Mitotane; Muscles; Pituitary ACTH Hypersecretion | 2023 |
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line; Cell Survival; Co | 2013 |
Treatment patterns in Cushing's disease patients in two large United States nationwide databases: application of a novel, graphical methodology.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenalectomy; Adult; Antineoplastic Agents, Hormonal; Co | 2015 |
Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
Topics: Adolescent; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Biomarkers; Female; Go | 2015 |
Successful therapy of Cushing's disease caused by an extrapituitary parasellar adenoma.
Topics: Adenoma; Aged; Female; Humans; Magnetic Resonance Imaging; Mitotane; Pituitary ACTH Hypersecretion; | 2010 |
Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Hormonal; Cohort Studies; Female; Hormone Antagonist | 2012 |